Overcoming Multidrug Resistance in Cancer: An Update on the Clinical Strategy of Inhibiting P-Glycoprotein

Multidrug resistance in cancer: role of ATP–dependent transporters

2002 • 5,195 citations

BIOCHEMISTRY OF MULTIDRUG RESISTANCE MEDIATED BY THE MULTIDRUG TRANSPORTER

1993 • 3,515 citations

BIOCHEMICAL, CELLULAR, AND PHARMACOLOGICAL ASPECTS OF THE MULTIDRUG TRANSPORTER

1999 • 2,049 citations

The Human ATP-Binding Cassette (ABC) Transporter Superfamily

2001 • 1,705 citations

The Human ATP-Binding Cassette (ABC) Transporter Superfamily

2001 • 1,110 citations

Multidrug resistance (MDR) in cancer

2000 • 1,013 citations

Immunohistochemical detection of P-glycoprotein: prognostic correlation in soft tissue sarcoma of childhood.

1990 • 462 citations

ABC Transporters as Phenotypic Markers and Functional Regulators of Stem Cells

2002 • 461 citations

P-Glycoprotein Expression as a Predictor of the Outcome of Therapy for Neuroblastoma

1991 • 447 citations

In vitro and in vivo reversal of P-glycoprotein-mediated multidrug resistance by a novel potent modulator, XR9576.

2001 • 349 citations

Reversal of P-glycoprotein-mediated multidrug resistance by a potent cyclopropyldibenzosuberane modulator, LY335979.

1996 • 329 citations

The molecular interaction of the high affinity reversal agent XR9576 with P‐glycoprotein

1999 • 258 citations

P-glycoprotein and cytochrome P-450 3A inhibition: dissociation of inhibitory potencies.

1999 • 250 citations

Circumvention of breast cancer resistance protein (BCRP)-mediated resistance to camptothecins in vitro using non-substrate drugs or the BCRP inhibitor GF120918.

2001 • 237 citations

Rapid activation of MDR1 gene expression in human metastatic sarcoma after in vivo exposure to doxorubicin.

1999 • 230 citations

The P-glycoprotein multidrug transporter

1996 • 219 citations

Resistance modification by PSC-833, a novel non-immunosuppressive cyclosporin A

1991 • 218 citations

Clinical trials of p-glycoprotein reversal in solid tumours

1996 • 210 citations

Discovery and characterization of OC144-093, a novel inhibitor of P-glycoprotein-mediated multidrug resistance.

2000 • 196 citations

Phase I study of etoposide with SDZ PSC 833 as a modulator of multidrug resistance in patients with cancer.

1996 • 179 citations

Selectivity of the multidrug resistance modulator, LY335979, for P-glycoprotein and effect on cytochrome P-450 activities.

1999 • 173 citations

Reversal of P-glycoprotein mediated multidrug resistance by novel anthranilamide derivatives

1999 • 160 citations

Treatment of Refractory and Relapsed Acute Myelogenous Leukemia With Combination Chemotherapy Plus the Multidrug Resistance Modulator PSC 833 (Valspodar)

1999 • 152 citations

Phase I and pharmacokinetic study of paclitaxel in combination with biricodar, a novel agent that reverses multidrug resistance conferred by overexpression of both MDR1 and MRP.

1998 • 146 citations

Combining cyclosporin with chemotherapy controls intraocular retinoblastoma without requiring radiation.

1996 • 141 citations

Modulation of P‐glycoprotein but not MRP1‐ or BCRP‐mediated drug resistance by LY335979

2002 • 138 citations

MDR Expression in Normal Tissues: Pharmocologic Implication for the Clinical Use of P-Glycoprotein Inhibitors

1995 • 134 citations

Chemosensitization and drug accumulation effects of VX-710, verapamil, cyclosporin A, MS-209 and GF120918 in multidrug resistant HL60/ADR cells expressing the multidrug resistance-associated protein MRP

1997 • 134 citations

Cellular and biochemical characterization of VX-710 as a chemosensitizer

1997 • 131 citations

Phase I trial of XR9576 in healthy volunteers demonstrates modulation of P-glycoprotein in CD56+ lymphocytes after oral and intravenous administration.

2000 • 123 citations

Treatment of Refractory and Relapsed Acute Myelogenous Leukemia With Combination Chemotherapy Plus the Multidrug Resistance Modulator PSC 833 (Valspodar)

1999 • 122 citations

The multidrug resistance modulator valspodar (PSC 833) is metabolized by human cytochrome P450 3A. Implications for drug-drug interactions and pharmacological activity of the main metabolite.

1998 • 104 citations

Phase II Study of Paclitaxel and Valspodar (PSC 833) in Refractory Ovarian Carcinoma: A Gynecologic Oncology Group Study

2001 • 91 citations

Phase I Study of Infusional Paclitaxel in Combination With the P-Glycoprotein Antagonist PSC 833

2001 • 89 citations

A dose-finding and pharmacokinetic study of reversal of multidrug resistance with SDZ PSC 833 in combination with doxorubicin in patients with solid tumors.

1997 • 87 citations

Pharmacological characterization of LY335979: A potent cyclopropyldibenzosuberane modulator of P-glycoprotein

1997 • 86 citations

Phase I/II Study of the P-Glycoprotein Modulator PSC 833 in Patients With Acute Myeloid Leukemia

2001 • 85 citations

Development of Multidrug-Resistance Convertors: Sense or Nonsense?

2000 • 84 citations

Phase I Study of Paclitaxel in Combination With a Multidrug Resistance Modulator, PSC 833 (Valspodar), in Refractory Malignancies

2000 • 83 citations

A phase I trial of doxorubicin, paclitaxel, and valspodar (PSC 833), a modulator of multidrug resistance.

2001 • 79 citations

A Phase I study of infusional vinblastine in combination with the p-glycoprotein antagonist PSC 833 (valspodar)

2001 • 78 citations

Flow cytometric assay of modulation of P-glycoprotein function in whole blood by the multidrug resistance inhibitor GG918.

1996 • 67 citations

Reversal of typical multidrug resistance by cyclosporin and its non-immunosuppressive analogue SDZ PSC 833 in Chinese hamster ovary cells expressing themdr1 phenotype

1992 • 66 citations

Phase I/II Trial of the Multidrug-Resistance Modulator Valspodar Combined With Cisplatin and Doxorubicin in Refractory Ovarian Cancer

2001 • 62 citations

A phase I study of induction chemotherapy for older patients with newly diagnosed acute myeloid leukemia (AML) using mitoxantrone, etoposide, and the MDR modulator PSC 833: a Southwest Oncology Group study 9617

2000 • 57 citations

BIRICODAR (VX-710; Incel™): an effective chemosensitizer in neuroblastoma

1999 • 53 citations

Chemosensitisation and drug accumulation effects of VX-710, verapamil, cyclosporin A, MS-209 and GF120918 in multidrug resistant HL60/ADR cells expressing the multidrug resistance-associated protein MRP

1997 • 53 citations

Single static view 99mTc-sestamibi scintimammography predicts response to neoadjuvant chemotherapy and is related to MDR expression

2002 • 42 citations

Incidence of P-glycoprotein overexpression and multidrug resistance (MDR) reversal in adult soft tissue sarcoma

2000 • 35 citations

Assessment of systemic toxicity in children receiving chemotherapy with cyclosporine for sarcoma

2000 • 24 citations

Assessment of the classical MDR phenotype in epithelial ovarian carcinoma using primary cultures: a feasibility study.

2002 • 7 citations